E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute sports-related traumatic blunt soft tissue injury/contusion |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10041738 |
E.1.2 | Term | Sports injury |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to assess the efficacy of a new ibuprofen gel versus placebo in the topical treatment of acute sports impact injuries/contusions.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objective will be to evaluate the tolerability of the gel in comparison to placebo. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Only Patients to whom all of the following conditions apply will be randomised: i) Age: 18-60 years ii) Sex: Both male or female patients may be included. iii) Normal general health iv) Primary diagnosis: fresh sports-related blunt soft tissue injury. (Time elapse between traumatic event and inclusion not longer than 3 hours). v) Injury not requiring hospitalisation. vi) The basic value of the algometric measurement on the injured site is less than or equal to 50% of the respective value at the contralateral site. vii) Pain on movement at baseline at least 50mm on a 100mm VAS. viii) The absolute sensitivity to pain on the contra lateral site is at least 2.5 N/cm2. ix) Written informed consent. x) The size of the traumatisation must be at least 25cm2 and maximal 150cm2.
|
|
E.4 | Principal exclusion criteria |
Patients to whom any of the following conditions apply must not be randomised: i) History of blood coagulation disorders. ii) A history of significant disease deemed by the investigator to render the patient unsuitable for inclusion. iii) Any significant ongoing painful condition other than that associated with the sports-related injury. iv) Any other treatment or medication that my interfere with the trial (e.g. corticosteroids) up to 3 days prior to the trial, except RICE (Rest, Ice, Compression, Elevation). v) Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of the study medication. vi) A history of psychotic illness, attempted suicide, or neurosis. vii) A positive history of drug or alcohol abuse within the past year. viii) Those taking any concomitant medications that might confound assessments of pain relief, such as psychotropic drugs, antidepressants, sedative –hypnotics taken within fives times of their elimination half lives. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if the patient has been on a stable dose for at least four weeks prior to Visit 1 (screening) and remain on this dose throughout the study. ix) Any other treatment or medication, that interferes with the conduct of the trial, except RICE (Rest, Ice, Compression, Elevation). x) Women of childbearing potential, who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch, an intrauterine device, abstinence [should the patient become sexually active, she must agree to use a double barrier method] or condoms/diaphragm and spermicide). A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy). xi) Any previous history of allergy or known intolerance to any of the drugs or formulation constituents which, in the Investigator’s opinion, might preclude use of an NSAID, including aspirin sensitive asthma or a previous allergic response to a NSAID, including bronchospasm, urticaria, angioedema and rhinitis. xii) Those previously randomised into this study. xiii) Patients who have received any analgesic, anti-inflammatory, antispasmodic or other therapy (except RICE) within 24 hours of taking the study medication. xiv) Those who have participated in a clinical trial in the previous 30 days calculated from time of last dosing in the prior trial to time of anticipated dosing in this trial. xv) Injured area is too hairy. xvi) Current skin disorders in the area to be treated. xvii) Open wounds to the area to be treated. xviii) Suspected fractures. xix) Suspected torn ligaments. xx) Head injuries. xxi) Pre-treatment of injury (any other therapy, except RICE). xxii) Anticipated poor compliance by the patient. xxiii) Patients with a known sensitivity to any of the materials/ drug/excipients in the gel respectively Paracetamol. xxiv) Relevant consumption of alcohol in the 24 hours prior to randomisation.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the area under the VAS assessment of pain on movement curve over Hours 0-72 (VAS AUC0-72h). The area under the curve will be calculated using the trapezoidal rule. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the last visit of the last subject undergoing the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |